Portola announces full results from positive phase 3 ANNEXA(TM)-R study
Portola announced full results from the first part of the Phase 3 ANNEXA™-R study, which is evaluating safety and efficacy of andexanet alfa with the Factor Xa inhibitor XARELTO®. Results showed the first part of this registration-enabling study met all primary and secondary endpoints. March 02, 2015